-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
AccuStem Sciences Announces Appointment of Sean McDonald to Board of Directors
AccuStem Sciences Announces Appointment of Sean McDonald to Board of Directors
LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today the appointment of Sean McDonald to its Board of Directors which will now comprise five members.
"We are pleased to welcome Sean to the board and believe his experience building and leading healthcare organizations and securing funding for early-stage companies will be invaluable to our mission at AccuStem," said Wendy Blosser, Chief Executive Officer and board member of AccuStem.
Sean joins the AccuStem board while serving as the CEO of Ocugenix, a therapeutics company focused on the development and commercialization of therapies for ocular diseases caused by excessive fibrosis and blood vessels in the eye.
Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Prior to that, from 2001 to 2014, Sean served as the CEO of Precision Therapeutics, one of the first biotechnology companies to marry breakthroughs in understanding of cancer biology and the use of machine learning with the goal of developing products that would help cancer patients get the most effective cancer treatment. From 2002 to 2008, Sean was also a director on the board of Respironics where he was a member of the audit and compensation committees leading up to its $5.1 billion acquisition by Phillips.
Sean started his career in healthcare by founding Automated Healthcare which was one of the first companies to develop systems for automating the dispensing and administration of medication in hospital pharmacies. Mr. McDonald grew the organization from its inception to over 1,000 employees and oversaw the building of market access, clinical, product development and sales and marketing organizations. Automated Healthcare was ultimately acquired by McKesson Corporation where Sean became President of the automation group.
"I am delighted to join the AccuStem team at such a pivotal time for the company," said Sean McDonald. "As genomic testing serves an increasingly important role in oncology care it will be critical that companies are able to commercialize novel tests that address unanswered clinical questions. With my background in scaling companies from inception to exit, and past working experience with the current leadership team, I believe I will be able to help the company execute its growth strategy and achieve its long term goals."
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor "stemness", we believe our tools will help care teams better understand the biology of each patient's cancer, leading to more informed decision making. For more information, please visit .
Media Contact:
Jeff Fensterer, Chief Operations Officer
Phone: 415-640-6010
Email: jeff@accustem.com
Investor Contact:
Wendy Blosser, Chief Executive Officer
Email: investors@accustem.com
LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced today the appointment of Sean McDonald to its Board of Directors which will now comprise five members.
倫敦和鳳凰城,2022年11月16日(環球網)-致力於改善癌症患者預後的臨牀階段診斷公司AccuStem Sciences,Inc.(場外交易市場代碼:ACUT)今天宣佈任命肖恩·麥克唐納為董事會成員,董事會現在將由五名成員組成。
"We are pleased to welcome Sean to the board and believe his experience building and leading healthcare organizations and securing funding for early-stage companies will be invaluable to our mission at AccuStem," said Wendy Blosser, Chief Executive Officer and board member of AccuStem.
AccuStem首席執行官兼董事會成員温迪·布洛瑟説:“我們很高興歡迎肖恩加入董事會,並相信他在建立和領導醫療保健組織以及為初創公司爭取資金方面的經驗將對我們在AccuStem的使命起到無價的作用。
Sean joins the AccuStem board while serving as the CEO of Ocugenix, a therapeutics company focused on the development and commercialization of therapies for ocular diseases caused by excessive fibrosis and blood vessels in the eye.
肖恩在加入AccuStem董事會時擔任Ocugenix的首席執行官,Ocugenix是一家治療公司,專注於開發由眼內過度纖維化和血管引起的眼部疾病的治療方法並將其商業化。
Sean served as a director at Aethon, a healthcare technology business that automates hospital logistics, from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Prior to that, from 2001 to 2014, Sean served as the CEO of Precision Therapeutics, one of the first biotechnology companies to marry breakthroughs in understanding of cancer biology and the use of machine learning with the goal of developing products that would help cancer patients get the most effective cancer treatment. From 2002 to 2008, Sean was also a director on the board of Respironics where he was a member of the audit and compensation committees leading up to its $5.1 billion acquisition by Phillips.
2006年至2017年,肖恩在醫院物流自動化的醫療技術公司愛頓擔任董事員工。從2015年到2016年,麥克唐納是亞當斯資本管理公司的風險投資合夥人,這是一家專門從事早期應用技術投資的風險投資公司。在此之前,從2001年到2014年,肖恩擔任Precision Treeutics的首席執行官,該公司是首批將癌症生物學理解和機器學習的使用突破結合在一起的生物技術公司之一,目標是開發幫助癌症患者獲得最有效癌症治療的產品。2002年至2008年,肖恩也是董事公司董事會的成員,在該公司被菲利普斯以51億美元收購之前,他是審計和薪酬委員會的成員。
Sean started his career in healthcare by founding Automated Healthcare which was one of the first companies to develop systems for automating the dispensing and administration of medication in hospital pharmacies. Mr. McDonald grew the organization from its inception to over 1,000 employees and oversaw the building of market access, clinical, product development and sales and marketing organizations. Automated Healthcare was ultimately acquired by McKesson Corporation where Sean became President of the automation group.
肖恩從創立Automated Healthcare開始了他在醫療保健領域的職業生涯。Automated Healthcare是首批開發醫院藥房藥物分配和管理自動化系統的公司之一。麥克唐納先生將該組織從一開始就發展到1,000多名員工,並監督了市場準入、臨牀、產品開發以及銷售和營銷組織的建設。Automated Healthcare最終被麥凱森公司收購,肖恩成為自動化集團的總裁。
"I am delighted to join the AccuStem team at such a pivotal time for the company," said Sean McDonald. "As genomic testing serves an increasingly important role in oncology care it will be critical that companies are able to commercialize novel tests that address unanswered clinical questions. With my background in scaling companies from inception to exit, and past working experience with the current leadership team, I believe I will be able to help the company execute its growth strategy and achieve its long term goals."
肖恩·麥克唐納説:“我很高興能在公司如此關鍵的時刻加入AccuStem團隊。隨着基因組測試在腫瘤護理中發揮着越來越重要的作用,公司能夠將解決未回答的臨牀問題的新型測試商業化將是至關重要的。憑藉我在公司從成立到退出的過程中的背景,以及過去在當前領導團隊的工作經驗,我相信我將能夠幫助公司執行其增長戰略,實現其長期目標。
About AccuStem
關於AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor "stemness", we believe our tools will help care teams better understand the biology of each patient's cancer, leading to more informed decision making. For more information, please visit .
AccuStem是一家臨牀階段診斷公司,致力於優化所有癌症患者的預後和生活質量。我們計劃通過提供專利分子檢測來推動醫療保健領域的創新,以滿足從癌症篩查到治療和監測的未得到滿足的臨牀需求。通過詢問新的疾病途徑,如腫瘤的“莖”,我們相信我們的工具將幫助護理團隊更好地瞭解每個患者癌症的生物學,導致更明智的決策。欲瞭解更多信息,請訪問。
Media Contact:
Jeff Fensterer, Chief Operations Officer
Phone: 415-640-6010
Email: jeff@accustem.com
媒體聯繫人:
首席運營官Jeff·芬斯特爾
電話:415-640-6010
電子郵件:Jeff@accustem.com
Investor Contact:
Wendy Blosser, Chief Executive Officer
Email: investors@accustem.com
投資者聯繫方式:
首席執行官温迪·布洛瑟
電子郵件:Investors@accustem.com
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧